An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner

Growth Hormone and IGF Research

Volumn 18, Issue 3, 2008, Pages 188-197

  Shahjee, H ^a   Bhattacharyya, N ^a   Zappala, G ^a   Wiench, M ^b   Prakash, S ^a   Rechler, M M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Human prostate cancer cells; IGFBP 3

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; HYBRID PROTEIN; LIPOCORTIN 5; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3; SIGNAL PEPTIDE; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; FRAGMENTATION REACTION; GENE MUTATION; HUMAN; HUMAN CELL; INCUBATION TIME; INTERNALIZATION; MUTANT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; STAINING;

APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; SOMATOMEDINS;

EID: 41849091138     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.08.006     Document Type: Article

References (61)

1. Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272 18 (1997) 12181-12188
2. Butt A.J., Firth S.M., King M.A., and Baxter R.C. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J. Biol. Chem. 275 50 (2000) 39174-39181
3. Hong J., Zhang G., Dong F., and Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J. Biol. Chem. 277 12 (2002) 10489-10497
4. Gucev Z.S., Oh Y., Kelley K.M., and Rosenfeld R.G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 56 7 (1996) 1545-1550
5. Rajah R., Lee K.W., and Cohen P. Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of BCL-2 phosphorylation. Cell Growth Differ. 13 4 (2002) 163-171
6. Vasylyeva T.L., Chen X., and Ferry Jr. R.J. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm. IGF Res. 15 3 (2005) 207-214
7. Ryan K.M., and Vousden K.H. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell Biol. 18 7 (1998) 3692-3698
8. Grimberg A., Liu B., Bannerman P., El-Deiry W.S., and Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int. J. Oncol. 21 2 (2002) 327-335
9. Harms K.L., and Chen X. The c terminus of p53 family proteins is a cell fate determinant. Mol. Cell Biol. 25 5 (2005) 2014-2030
10. Hanafusa T., Yumoto Y., Nouso K., et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 176 2 (2002) 149-158
11. Chang Y.S., Kong G., Sun S., et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin. Cancer Res. 8 12 (2002) 3796-3802
12. Wang L., Habuchi T., Tsuchiya N., et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 63 15 (2003) 4407-4411
13. Deal C., Ma J., Wilkin F., et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab. 86 3 (2001) 1274-1280
14. Ramachandran S., Liu P., Young A.N., et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 24 1 (2005) 188-198
15. Prieur A., Tirode F., Cohen P., and Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell Biol. 24 16 (2004) 7275-7283
16. Benini S., Zuntini M., Manara M.C., et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int. J. Cancer 119 5 (2006) 1039-1046
17. Spagnoli A., Torello M., Nagalla S.R., et al. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J. Biol. Chem. 277 (2002) 18860-18867
18. Silha J.V., Sheppard P.C., Mishra S., et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147 5 (2006) 2112-2121
19. Oh Y., Muller H.L., Pham H., and Rosenfeld R.G. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 268 35 (1993) 26045-26048
20. Huang S.S., Ling T.Y., Tseng W.F., et al. Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. Faseb J. 17 14 (2003) 2068-2081
21. Ricort J.M. Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm. IGF Res. 14 4 (2004) 277-286
22. Lee K.W., Liu B., Ma L., et al. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J. Biol. Chem. 279 1 (2004) 469-476
23. Bhattacharyya N., Pechhold K., Shahjee H., et al. Non-secreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J. Biol. Chem. 281 34 (2006) 24588-24601
24. Giudice L.C., Farrell E.M., Pham H., Lamson G., and Rosenfeld R.G. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J. Clin. Endocrinol. Metab. 71 4 (1990) 806-816
25. Hossenlopp P., Segovia B., Lassarre C., Roghani M., Bredon M., and Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150k complex during pregnancy. J. Clin. Endocrinol. Metab. 71 4 (1990) 797-805
26. Angelloz-Nicoud P., and Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136 12 (1995) 5485-5492
27. Lalou C., Lassarre C., and Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137 8 (1996) 3206-3212
28. Lalou C., Sawamura S., Segovia B., Ogawa Y., and Binoux M. Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity. CR Acad. Sci. III 320 8 (1997) 621-628
29. Hashimoto R., Ono M., Fujiwara H., et al. Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J. Biol. Chem. 272 44 (1997) 27936-27942
30. Firth S.M., Ganeshprasad U., and Baxter R.C. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J. Biol. Chem. 273 5 (1998) 2631-2638
31. Blat C., Villaudy J., and Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. Clin. Invest. 93 5 (1994) 2286-2290
32. Lassarre C., and Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 134 3 (1994) 1254-1262
33. Galanis M., Firth S.M., Bond J., et al. Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J. Endocrinol. 169 1 (2001) 123-133
34. Vorwerk P., Hohmann B., Oh Y., Rosenfeld R.G., and Shymko R.M. Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N- and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor. Endocrinology 143 5 (2002) 1677-1685
35. Salahifar H., Firth S.M., Baxter R.C., and Martin J.L. Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells. Growth Horm. IGF Res. 10 6 (2000) 367-377
36. Zadeh S.M., and Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 138 7 (1997) 3069-3072
37. Maile L.A., Gill Z.P., Perks C.M., and Holly J.M. The role of cell surface attachment and proteolysis in the insulin-like growth factor (IGF)-independent effects of IGF-binding protein-3 on apoptosis in breast epithelial cells. Endocrinology 140 9 (1999) 4040-4045
38. Bernard L., Babajko S., Binoux M., and Ricort J.M. The amino-terminal region of insulin-like growth factor binding protein-3, (1-95)IGFBP-3, induces apoptosis of MCF-7 breast carcinoma cells. Biochem. Biophys. Res. Commun. 293 1 (2002) 55-60
39. Vorwerk P., Oh Y., Lee P.D., Khare A., and Rosenfeld R.G. Synthesis of IGFBP-3 fragments in a baculovirus system and characterization of monoclonal anti-IGFBP-3 antibodies. J. Clin. Endocrinol. Metab. 82 7 (1997) 2368-2370
40. Elbi C., Misteli T., and Hager G.L. Recruitment of dioxin receptor to active transcription sites. Mol. Biol. Cell 13 6 (2002) 2001-2015
41. Kroemer G., El-Deiry W.S., Golstein P., et al. Classification of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ. 12 Suppl 2 (2005) 1463-1467
42. Wu H.B., Kumar A., Tsai W.C., Mascarenhas D., Healey J., and Rechler M.M. Characterization of the inhibition of DNA synthesis in proliferating mink lung epithelial cells by insulin-like growth factor binding protein-3. J. Cell Biochem. 77 2 (2000) 288-297
43. Oh Y., Muller H.L., Lamson G., and Rosenfeld R.G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in hs578T human breast cancer cells. Cell surface binding and growth inhibition. J. Biol. Chem. 268 20 (1993) 14964-14971
44. Booth B.A., Boes M., Andress D.L., et al. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. 5 1 (1995) 1-17
45. Yang Y.W., Yanagishita M., and Rechler M.M. Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans. Endocrinology 137 10 (1996) 4363-4371
46. Kubler B., Draeger C., John H., et al. Isolation and characterization of circulating fragments of the insulin-like growth factor binding protein-3. FEBS Lett. 518 1-3 (2002) 124-128
47. Yamanaka Y., Fowlkes J.L., Wilson E.M., Rosenfeld R.G., and Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140 3 (1999) 1319-1328
48. Schedlich L.J., Le Page S.L., Firth S.M., Briggs L.J., Jans D.A., and Baxter R.C. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J. Biol. Chem. 275 31 (2000) 23462-23470
49. Zhao Y., Yin P., Bach L.A., and Duan C. Several acidic amino acids in the N-domain of insulin-like growth factor-binding protein-5 are important for its transactivation activity. J. Biol. Chem. 281 20 (2006) 14184-14191
50. Chipuk J.E., and Green D.R. Do inducers of apoptosis trigger caspase-independent cell death?. Nat. Rev. Mol. Cell Biol. 6 3 (2005) 268-275
51. H-Zadeh A.M., Collard T.J., Malik K., Hicks D.J., Paraskeva C., and Williams A.C. Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int. J. Oncol. 29 5 (2006) 1279-1286
52. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 6 (2002) 824-854
53. Bach L.A., Headey S.J., and Norton R.S. IGF-binding proteins - the pieces are falling into place. Trends Endocrinol. Metab. 16 5 (2005) 228-234
54. Booth B.A., Boes M., and Bar R.S. IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments. Am. J. Physiol. 271 3 Pt 1 (1996) E465-E470
55. Fielder P.J., Rosenfeld R.G., Graves H.C., et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul. 4 4 (1994) 164-172
56. Okabe E., Kajihara J., Usami Y., and Hirano K. The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3. FEBS Lett. 447 1 (1999) 87-90
57. Fowlkes J.L., Enghild J.J., Suzuki K., and Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269 41 (1994) 25742-25746
58. Miyamoto S., Yano K., Sugimoto S., et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 64 2 (2004) 665-671
59. Zwad O., Kubler B., Roth W., et al. Decreased intracellular degradation of insulin-like growth factor binding protein-3 in cathepsin L-deficient fibroblasts. FEBS Lett. 510 3 (2002) 211-215
60. Hollowood A.D., Stewart C.E., Perks C.M., et al. Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions. J. Cell Biochem. 86 3 (2002) 583-589
61. Singh B., Charkowicz D., and Mascarenhas D. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J. Biol. Chem. 279 1 (2004) 477-487